<?xml version='1.0' encoding='utf-8'?>
<document id="24582422"><sentence text="Spinosad is a potent inhibitor of canine P-glycoprotein." /><sentence text="Inhibition of the drug transporter P-glycoprotein (P-gp) by the oral flea preventative spinosad has been suggested as the underlying cause of the drug-drug interaction with ivermectin"><entity charOffset="173-183" id="DDI-PubMed.24582422.s2.e0" text="ivermectin" /></sentence><sentence text=" In this study, an in vitro model consisting of canine cells was validated to describe the inhibitory effect of drugs on canine P-gp" /><sentence text=" In this model, ivermectin, cyclosporin, verapamil, loperamide and ketoconazole inhibited P-gp function with IC50 values ranging from 0"><entity charOffset="16-26" id="DDI-PubMed.24582422.s4.e0" text="ivermectin" /><entity charOffset="28-39" id="DDI-PubMed.24582422.s4.e1" text="cyclosporin" /><entity charOffset="41-50" id="DDI-PubMed.24582422.s4.e2" text="verapamil" /><entity charOffset="52-62" id="DDI-PubMed.24582422.s4.e3" text="loperamide" /><entity charOffset="67-79" id="DDI-PubMed.24582422.s4.e4" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e0" e2="DDI-PubMed.24582422.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e0" e2="DDI-PubMed.24582422.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e0" e2="DDI-PubMed.24582422.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e0" e2="DDI-PubMed.24582422.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e0" e2="DDI-PubMed.24582422.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e1" e2="DDI-PubMed.24582422.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e1" e2="DDI-PubMed.24582422.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e1" e2="DDI-PubMed.24582422.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e1" e2="DDI-PubMed.24582422.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e2" e2="DDI-PubMed.24582422.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e2" e2="DDI-PubMed.24582422.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e2" e2="DDI-PubMed.24582422.s4.e4" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e3" e2="DDI-PubMed.24582422.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24582422.s4.e3" e2="DDI-PubMed.24582422.s4.e4" /></sentence><sentence text="1 to 3" /><sentence text="7 μmol/L" /><sentence text=" Spinosad was a potent inhibitor of canine P-gp with an IC50 value of 0" /><sentence text="27 μmol/L or 0" /><sentence text="2 μg/mL" /><sentence text=" The risk of spinosad causing P-gp related drug-drug interactions in the dog could be predicted by the IC50 value, the oral dosage and plasma concentrations" /><sentence text="" /></document>